FDA approves subcutaneous administration of Entyvio (vedolizumab) for maintenance therapy in moderately to severely active Crohn’s disease – Takeda
Takeda announced that the FDA has approved Entyvio (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy… read more.
